Reuters - Video

Edition: US | UK | IN | CN | JP

Video

Breakingviews: AstraZeneca's struggling defence

Tuesday, November 18, 2014 - 04:50

The UK pharma group fought Pfizer's $120 billion bid by promising growth. But its defence has been aided most by U.S. curbs on tax-driven M&A, says Reuters Breakingviews.

Press CTRL+C (Windows), CMD+C (Mac), or long-press the URL below on your mobile device to copy the code

Breakingviews: AstraZeneca's struggling defence

Tuesday, November 18, 2014 - 04:50